An improved blood substitute: In vivo evaluation of its renal effects

ASAIO Journal

Volumn 43, Issue 5, 1997, Pages

  Simoni, Jan ^a   Simoni, Grace ^a   Hartsell, Alan ^a   Feola, Mario ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; HEMOGLOBIN; PROTEINS; SIZE EXCLUSION CHROMATOGRAPHY; TOXICITY; UROLOGY;

ISOELECTRIC FOCUSING METHOD; NEPHROTOXICITY; RENAL EFFECTS;

BLOOD SUBSTITUTES;

ACETYLGLUCOSAMINIDASE; ADENOSINE; ADENOSINE TRIPHOSPHATE; CHLORIDE ION; HEMOGLOBIN; POTASSIUM ION; SODIUM ION;

ANIMAL TISSUE; BLOOD SUBSTITUTION; CONFERENCE PAPER; CONJUGATION; ELECTROLYTE EXCRETION; GEL PERMEATION CHROMATOGRAPHY; GLOMERULUS FILTRATION; HEMOGLOBINURIA; HISTOPATHOLOGY; ISOELECTRIC FOCUSING; MALE; NEPHROTOXICITY; NONHUMAN; PROTEIN CROSS LINKING; PROTEIN MODIFICATION; PROTEINURIA; RAT; RECOMBINANT DNA TECHNOLOGY; TECHNIQUE;

EID: 0031239389     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002480-199703000-00046     Document Type: Conference Paper

References (86)

1. Chang TMS: Past, present and future perspectives on the 40th anniversary of hemoglobin based red blood cell substitutes. Artif Cells Blood Substit Immobil Biotechnol 24: ix-xxiv, 1996.
2. Erickson D: Will blood substitute deliver? Start-Up Windhovers Rev Emerg Med Ventures 1: 8-14, 1996.
3. Marwick C: More than a trickle of interest in blood substitutes. JAMA 271: 895, 1994.
4. Winslow RM: Hemoglobin-Based Red Cell Substitutes. Baltimore, John Hopkins University Press, 1992.
5. Hess JR, Macdonald VW, Gomez CS, Coppes V: Increased vascular resistance with hemoglobin based oxygen carriers. Artif Cells Blood Substit Immobil Biotechnol 22: 361-372, 1994.
6. Koch T, Ducker HP, Heller A, et al.: Effect of stroma-free hemoglobin solutions on pulmonary vascular resistance and mediator release in the isolated perfused rabbit lung. Shock 1: 146-152, 1994.
7. MacDonald VW, Motterlini R: Vasoconstrictor effects in isolated rabbit heart perfused with bis (3,5-dibromosalicyl) fumarate cross-linked hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 22: 565-575, 1994.
8. Faasses AE, Sundby SR, Panter SS, et al.: Hemoglobin: a lifesaver and an oxidant how to tip the balance. Biomater Artif Cells Artif Organs 16: 93-194, 1988.
9. Simoni J, Feola M, Canizaro PC: Generation of free oxygen radicals and the toxicity of hemoglobin solutions. Biomater Artif Cells Artif Organs 18: 198-202, 1990.
10. Bassett P: Oxygen therapeutics: hemoglobin's new role - development opportunities. Drug Market Dev 7: 2-5, 1996.
11. Kasper SM, Walter M, Grune F, et al.: Effect of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilation for elective abdominal aortic surgery. Anesth Analg 83: 921-927, 1996.
12. Swam SK, Halstenson CE, Collins AJ, et al.: Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. Am J Kidney Dis 26: 918-923, 1995.
13. Viele MK, Weiskopf RB, Fisher D: Recombinant human hemoglobin does not affect renal function in humans: analysis of safety and pharmacokinetics. Anesthesiology 86: 848-858, 1997.
14. Deen WM, Bohrer MP, Robertson CR, Brenner BM: Determinants of the transglomerular passage of macromolecules. Fed Proc 36: 2614-2618, 1977.
15. Brenner BM, Hostetter TH, Humes HD: Glomerular permselectivity: barrier function based on discrimination of molecular size and charge. Am J Physiol 234: F455-F460, 1978.
16. Parker JC: Transvascular clearance and distribution of charged macromolecules in ANTU lung injury. J Appl Physiol 60: 1221-1229, 1986.
17. Thurauf N, Dermietzel R, Kalweit R: Surface charges associated with fenestrated brain capillaries. I. In vitro labeling of anionic sites. J Ultrastruct Res 84: 103-110, 1983.
18. Hess JR: Blood substitutes. Semin Hematol 33: 369-378, 1996.
19. Simoni J, Simoni G, Feola M: Chromatographic analysis of biopolymers distribulion in "poly-hemoglobin," an intermolecularly crosslinked hemoglobin solution. Anal Chim Acta 279: 73-88, 1993.
20. Bucci E, Razynska A, Urbaitis B, Fronticelli C: Pseudo cross-link of human hemoglobin with mono-(3,5,-dibromosalicyl) fumarate. J Biol Chem 264: 6191-6195, 1989.
21. Feola M Simoni J, Canizaro PC: Polyhemoglobin stabilized by purine derivatives and glutathione. European patent no. EP 507870, 1996.
22. Feola M, Simoni J, Canizaro PC: Blood substitute. U.S. patent no. 5439882, 1995.
23. Feola M, Simoni J, Angelillo R, et al.: Clinical trial of a hemoglobin based blood substitute in patients with sickle cell anemia. Surg Gynecol Obstet 174: 379-386, 1992.
24. Simoni J, Simoni G, Newman G, Feola M: An improved blood substitute: in vivo evaluation of its hemodynamic effects. ASAIO J 42: M773-M782, 1996.
25. Feola M, Simoni J, Canizaro PC, et al.: Toxicity of polymerized hemoglobin solutions. Surg Gynecol Obstet 166: 211-222, 1988.
26. Feola M, Simoni J, Canizaro PC: Quality control of hemoglobin solutions: I. The purity of hemoglobin before modification. Artif Organs 15: 243-248, 1991.
27. Simoni J, Simoni G, Feola M, Canizaro PC: Evaluation of anion-exchange liquid chromatography for purification of hemoglobin from peptides and other proteins. Anal Chim Acta 249: 169-183, 1991.
28. Simoni J, Simoni G, Garcia EL, et al.: Protective effect of selenium on hemoglobin mediated lipid peroxidation in vivo. Artif Cells Blood Substit Immobil Biotechnol 23: 469-486, 1995.
29. Amberson WR: Blood substitutes. Biol Rev 12: 48-86, 1937.
30. Rabiner SF, Helbert JR, Lopas H, et al.: Evaluation of stroma-free hemoglobin solution for use as a plasma expander. J Exp Med 126: 1127-1142, 1967.
31. DeVenuto F, Friedman HI, Neville JR, et al.: Appraisal of hemoglobin solution as a blood substitute. Surg Gynecol Obstet 149: 417-436, 1979.
32. Velky TS, Lee ES, Maffuid PW, et al.: Peritoneal accumulation of infused stroma-free hemoglobin. Arch Surg 122: 355-357, 1987.
33. Savitzky JP, Doczi J, Black J, et al.: A clinical safety trial of stroma-free hemoglobin. Clin Pharmacol Ther 23: 73-80, 1978.
34. Bunn HF, Esham WT, Bull RW: The renal handling of hemoglobin. I. Glomerular filtration. J Exp Med 129: 909-924, 1969.
35. Bunn HF, Jandl JH: The renal handling of hemoglobin. II. Catabolism. J Exp Med 129: 925-934, 1969.
36. Benson P, Laver M, Morris KC: Novel polymerized cross-linked stroma free hemoglobin. U.S. patent no. 4001200, 1977.
37. Kampp M: Transcapillary exchange of large molecules: mammals, in Altman PL, Dittmer DS (eds), Respiration and Circulation, Bethesda, FASEB, 1971, pp. 504-509.
38. Haraldsson B, Ekholm C, Rippe B: Importance of molecular charge for the passage of endogenous macromolecules across continuous capillary walls, studies by serum clearance of lactate dehydrogenase (LDH) isoenzymes. Acta Physiol Scand 117: 123-130, 1983.
39. Dermietzel R, Thurauf N, Kalweit P: Surface charges associated with fenestrated brain capillaries. II. In vivo studies on the role of molecular charge in endothelial permeability. J Ultrastruct Res 84: 111-119, 1983.
40. 2). J Biol Chem 261: 9929-9937, 1971.
41. Benesh RE, Kwong S: Bis-pyridoxal polyphosphates: a new class of specific intramolecular crosslinking agents for hemoglobin. Biochem Biophys Res Commun 156: 9-14, 1988.
42. Smith CD, Schuscherba ST, Hess JR, et al.: Liver and kidney injury after administration of hemoglobin cross-linked with bis(3,5-dibromosalicyl) fumarate. Biomater Artif Cells Artif Organs 18: 251-261, 1990.
43. Urbaitis B, Lu YS, Fronticelli C, Bucci E: Renal excretion of pseudo-cross-linked human, porcine and bovine hemoglobin. Biochim Biophys Acta 1156: 50-56, 1992.
44. Cashon RE, Alayash AI: Reaction of human hemoglobin HbAo and two cross-linked derivatives with hydrogen peroxide: differential behavior of the ferryl intermediate. Arch Biochem Biophys 316: 461-469, 1995.
45. Chang JE, Wong JT: Synthesis of soluble dextran-hemoglobin complexes of different molecular sizes. Can J Biochem 55: 398-403, 1995.
46. Nho K, Abuchowski A: Bovine hemoglobin-polyethylene glycol conjugate as an oxygen-carrier. Biomater Artif Cells Immobil Biotechnol 19: 453, 1991.
47. Matsushita M, Yabuki A, Malchesky PS, Harasaki H, Nose Y: In vivo evaluation of a pyridoxylated-hemoglobin-polyoxyethylene conjugate. Biomater Artif Cells Immobil Biotechnol 16: 247-260, 1988.
48. Tam SC, Wong JT: Impairment of renal function by stroma-free hemoglobin in rats. J Lab Clin Med 111: 189-193, 1988.
49. Conover C, Lejeune L, Linberg R, et al.: Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat. Artif Cells Blood Substit Immobil Biotechnol 24: 599-611, 1996.
50. Matsushita M, Yabuki A, Chen JF, et al.: Renal effects of a pyridoxylated-hemoglobin-polyoxyethylene conjugate solution as a blood substitute in exchange transfusion. ASAIO Trans 34: 280-283, 1988.
51. Hsia JC: Pasteurizable, freeze-driable hemoglobin-based blood substitute. U.S. patent no. 4857636, 1989.
52. Bakker JC, Berbers GAM, Bleeker WK, den Boer PJ, Biessels TM: Preparation and characterization of crosslinked and polymerized hemoglobin solutions. Biomater Artif Cells Immobil Biotechnol 20: 233-241, 1992.
53. Gould SA, Sehgal LR, Rosen AL, et al.: The development of polymerized pyridoxylated hemoglobin solution as a red cell substitute. Ann Emerg Med 15: 1416-1419, 1986.
54. Marini MA, More GL, Christensen SM, et al.: Reexamination of the polymerization of pyridoxylated hemoglobin with glutaraldehyde. Biopolymers 29: 871-882, 1990.
55. Hsia JC, Song DL, Er SS, et al.: Pharmacokinetic studies in the rat on a o-raffinose polymerized human hemoglobin. Biomater Artif Cells Immobil Biotechnol 20: 587-595, 1992.
56. Lenz G, Junger H, Schneider M, et al.: Elimination of pyridoxylated polyhemoglobin after partial exchange transfusion in chimpanzees. Biomater Artif Cells Immobil Biotechnol 19: 699-708, 1991.
57. Kumar R: Recombinant hemologbins as blood substitutes: a bio-technology perspective [Minireview]. PSEBM 208: 150-158, 1995.
58. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142, 1991.
59. Hess JR, Fadare SO, Tolentino LS, et al: The intravascular persistence of cross linked human hemoglobin. Prof Clin Biol Res 319: 351-357, 1981.
60. Rose BD: Pathophysiology of Renal Disease, 2nd ed. New York, McGraw-Hill, 1987, pp. 469-488.
61. Melnick GF, Ladoulis CT, Cavallo T: Decreased anionic groups and increased permeability precedes deposition of immune complexes in the glomerular capillary wall. Am J Pathol 105: 114-120, 1981.
62. Fishman RM, Moore GL, Zegna A, Marini MA: High-performance liquid chromatographic evaluation of pyridoxal 5′-phosphate hemoglobin derivatives produced by different reduction procedures. J Chromatogr 532: 55-64, 1990.
63. Flamenbaum W, Gehr M, Gross M, Kaufman J, Hamburger R: Acute renal failure associated with myoglobinuria and hemoglobinuria, in Brenner BM, Lazarus JM (eds), Acute Renal Failure, Philadelphia, Saunders, 1983, pp. 269-282.
64. Pimstone NR: Renal degradation of hemoglobin. Semin Hematol 9: 31-42, 1972.
65. Tenhunen R, Marver HS, Schmid R: Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem 244: 6388-6394, 1969.
66. Tenhunen R, Marver HS, Schmid R: The enzymatic catabolism of hemoglobin: stimulation of microsomal heme oxygenase by hemin. J Lab Clin Med 75: 410-421, 1970.
67. Kutty RK, Daniel RF, Ryan DE, Levin W, Maines MD: Rat liver cytochrome P-450b, P-450b, and P-420c are degraded to biliverdin by heme oxygenase. Arch Biochem Biophys 260: 638-644, 1988.
68. Lahdevirta J, Tenhunen R: Heme catabolism in human kidneys, effect of various nephritides. Clin Chim Acta 77: 125-130, 1977.
69. Feola M, Simoni J, Tran R, Canizaro PC: Nephrotoxicity of hemoglobin solutions. Biomater Artif Cells Artif Organs 18: 233-249, 1990.
70. Ning J, Peterson LM, Anderson PJ, Biro GP: Systemic hemodynamic and renal effects of unmodified human SFHS in dogs. Biomater Artif Cells Immobil Biotechnol 20: 723-727, 1992.
71. Rose BD Black RM: Manual of Clinical Problems in Nephrology, Boston, Little, Brown, 1988, pp. 3-244.
72. Noto A, Ogawa Y, Mori S, et al.: Simple, rapid spectrophotometry of urinary A-acetyl-β-D-glucosaminidase, with use of a new chromogenic substrate. Clin Chem 29: 1713-1716, 1983.
73. Paller MS, Hoidal JR, Ferris TF: Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest 74: 1156-1164, 1984.
74. Simoni J, Simoni G, Lox CD, Feola M: Reaction of human endothelial cells to bovine hemoglobin solutions and tumor necrosis factor. Artif Cells Blood Substit Immobil Biotechnol 22: 777-787, 1994.
75. Yoshida Y, Kashiba K, Niki E: Free radical mediated oxidation of lipid induced by hemoglobin in aqueous dispersions. Biochim Biophys Acta 1201: 165-172, 1994.
76. Simoni J, Simoni G, Lox CD, et al.: Evidence for the direct inhibition of endothelin-1 secretion by hemoglobin in human endothelial cells. ASAIO J 41: M641-651, 1995.
77. Simoni J, Simoni G, Lox CD, et al.: Cytokines and PAF release from human monocytes and macrophages: effect of hemoglobin and contaminants. Artif Cells Blood Substit Immobil Biotechnol 22: 525-534, 1994.
78. Simoni J, Simoni G, Lox CD, et al.: Modified Hb solution with desired pharmacological properties, does not activate the transcription factor NF-kappa B in human vascular endothelial cells. Artif Cells Blood Substit Immobil Biotechnol 25: 193-210, 1997.
79. Simoni J, Simoni G, Lox CD, et al.: Expression of adhesion molecules and von Willebrand factor in human coronary artery endothelial cells incubated with differently modified hemoglobin solutions. Artif Cells Blood Substit Immobil Biotechnol 25: 211-225, 1997.
80. Dalay JW, Kuroda Y, Phillis JW, Shimazu H, Ui M: Physiology and Pharmacology of Adenosine Derivatives, New York, Raven Press, 1983, pp. 1-299.
81. Haynes J Jr, Obiako B, Thompson WJ, Downey J: Adenosine induced vasodilation: receptor characterization in pulmonary circulation. Am J Physiol 268: H1862-1868, 1995.
82. Yamagishi T, Yaangisawa T, Satoh K, et al.: Relaxant mechanism of cyclic AMP-increasing agents in porcine coronary artery. Eur J Pharmacol 251: 253-262, 1994.
83. Matsunaga T, Okumura K, Tsunoda R, et al.: Role of adenosine in regulation of coronary flow in dogs with inhibited synthesis of endothelium-derived nitric oxide. Am J Physiol 270: H427-434, 1996.
84. Maggirwar SB, Dhanraj DN, Somani SM, Ramkumar V: Adenosine acts as an endogenous activator of the cellular antioxidant defense system. Biochem Biophys Res Commun 201: 508-515, 1994.
85. Bouma MG, Van Der Wildenberg Fajm, Buurman WA: Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol 270: C522-C529, 1996.
86. Cronstein BN: Adenosine, and endogenous anti-inflammatory agent. J Appl Physiol 76: 5-13, 1994.